www.akelapharma.com
Toronto Stock Exchange Symbol: AKL
MONTREAL, July 8 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that as previously requested by the FDA, it has
started over again the required inhalation toxicology studies. The studies
performed at US based CRO are expected to produce results allowing Akela to
start the longer term safety arm of the Fentanyl TAIFUN(R) Phase III clinical
trial in patients in the second quarter of 2009.
"We are still on track to deliver the required toxicology studies results
in time to allow us to meet our previously disclosed regulatory submission
timelines of Q1-2010 for the E.U. and Q3-2010 for the U.S." said Dr. Halvor
Jaeger, CEO of Akela Pharma Inc.
About Akela Pharma Inc.:
Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation and pain
markets. Its lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, growth hormone deficiencies and controlled substance abuse deterrent
formulations. PharmaForm, Akela's wholly owned subsidiary, is a leading
specialty contract service provider offering a portfolio of innovative
technologies in drug product development, manufacturing and analytical testing
to the pharmaceutical and biotechnology industries. Through its diverse
offerings, PharmaForm solutions help clients reduce development costs and
accelerate time-to-market.
Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 21.6 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Akela Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
%SEDAR: 00003466EF
For further information: visit Akela's website at www.akelapharma.com,
or contact: Frédéric Dumais, Vice-President, Investor Relations, (514)
315-3330 ext. 106, Fax: (514) 315-3325
